tbuckley/cabot-search huggingface dataset:
Gastroesophageal Reflux Disease and Barrett’s Esophagus
Authors: H. Koop
Journal: Endoscopy (2004)

Gastroesophageal reflux disease (GERD) is a very common disorder, mainly occurring in Western countries. The nonerosive form of GERD, which occurs in more than half of the patients affected, deserves particular attention. Administering symptomatic therapy without a prior endoscopic examination has become an attractive option, since it also provides diagnostic information. Proton-pump inhibitors (PPIs) have become established as the standard therapy, but new insights into the pathophysiology of the condition may lead to new treatment options using γ-aminobutyric acid (GABA) agonists. Endoscopic therapy is still at the experimental stage and has yet to prove its value as an alternative to PPI and surgery. However, it is questionable whether antireflux surgery is more cost-effective in the longer term.Gastroenterologists are now much more aware of Barrett's esophagus than was the case a few years ago. Barrett's esophagus is a frequent finding in patients with reflux symptoms, but is a rare cause of death in affected patients. For several reasons, there is a large gap between recommendations regarding surveillance, on the one hand, and everyday practice on the other. New diagnostic procedures such as chromoendoscopy may allow better detection of premalignant and malignant alterations in metaplastic mucosa, but the safety of such techniques has been questioned. Prophylactic ablation is a debatable approach, whereas endoscopic interventions in patients with high-grade dysplasia and early adenocarcinoma are continuing to develop as attractive alternatives to esophagectomy in selected patients. It remains to be seen whether chemoprevention using cyclooxygenase-2 (COX-2) inhibitors should be carried out in high-risk patients with Barrett's esophagus, in order to prevent malignant transformation to esophageal cancer.
Particulate Air Pollution and Daily Mortality on Utah's Wasatch Front
Authors: C. Arden Pope, Randy W. Hill, G. Martin Villegas
Journal: Environmental Health Perspectives (1999)

Reviews of daily time-series mortality studies from many cities throughout the world suggest that daily mortality counts are associated with short-term changes in particulate matter (PM) air pollution. One U.S. city, however, with conspicuously weak PM-mortality associations was Salt Lake City, Utah; however, relatively robust PM-mortality associations have been observed in a neighboring metropolitan area (Provo/Orem, Utah). The present study explored this apparent discrepancy by collecting, comparing, and analyzing mortality, pollution, and weather data for all three metropolitan areas on Utah's Wasatch Front region of the Wasatch Mountain Range (Ogden, Salt Lake City, and Provo/Orem) for approximately 10 years (1985-1995). Generalized additive Poisson regression models were used to estimate PM-mortality associations while controlling for seasonality, temperature, humidity, and barometric pressure. Salt Lake City experienced substantially more episodes of high PM that were dominated by windblown dust. When the data were screened to exclude obvious windblown dust episodes and when PM data from multiple monitors were used to construct an estimate of mean exposure for the area, comparable PM-mortality effects were estimated. After screening and by using constructed mean PM [less than/equal to] 10 microm in aerodynamic diameter (PM10) data, the estimated percent change in mortality associated with a 10-mg/m3 increase in PM10 (and 95% confidence intervals) for the three Wasatch Front metropolitan areas equaled approximately 1. 6% (0.3-2.9), 0.8% (0.3-1.3), and 1.0% (0.2-1.8) for the Ogden, Salt Lake City, and Provo/Orem areas, respectively. We conclude that stagnant air pollution episodes with higher concentrations of primary and secondary combustion-source particles were more associated with elevated mortality than windblown dust episodes with relatively higher concentrations of coarse crustal-derived particles.
Hantavirus Pulmonary Syndrome, United States 1993
Journal: JAMA (1994)

In June 1993, a newly recognized hantavirus was identified as the etiologic agent of an outbreak of severe respiratory illness (hantavirus pulmonary syndrome [HPS]) in the southwestern United States. Since this problem was recognized, sporadic cases have been identified from a wide geographic area in the western United States. This report summarizes the epidemiologic characteristics of HPS cases reported to CDC from May 1 through December 31, 1993.
Renal homotransplantation. Successful course following rapidly progressive glomerulonephritis
Authors: C. Costa
Journal: JAMA (1967)

Renal homotransplantation has been successful in a patient with rapidly progressive glomerulonephritis. This patient had normal serum complement levels at the time of operation. Since the serum complement concentration has been shown to parallel the activity of acute glomerulonephritis, normal complement levels would appear to indicate the disease was essentially inactive at the time of surgery. The results in this case support the conclusion that the activity of the preexisting glomerulonephritis plays an important role in the survival and function of the transplanted kidney.
The transcriptional repressor Tbx3 delineates the developing central conduction system of the heart
Authors: W HOOGAARS
Journal: Cardiovascular Research (2004)

Objective: The molecular mechanisms that regulate the formation of the conduction system are poorly understood. We studied the developmental expression pattern and functional aspects of the T-box transcription factor Tbx3, a novel marker for the murine central conduction system (CCS). Methods: The patterns of expression of Tbx3, and of Cx40, Cx43, and Nppa, which are markers for atrial and ventricular chamber-type myocardium in the developing heart, were analyzed in mice by in situ hybridization and three-dimensional reconstruction analysis. The function of Tbx3 in regulating Nppa and Cx40 promoter activity was studied in vitro. Results: In the formed heart, Tbx3 is expressed in the sinoatrial node (SAN), atrioventricular node (AVN), bundle and proximal bundle branches (BBs), as well as the internodal regions and the atrioventricular region. Throughout cardiac development, Tbx3 is expressed in an uninterrupted myocardial domain that extends from the sinoatrial node to the atrioventricular region. This expression domain is present in the looping heart tube from E8.5 onwards. Expression of the chamber-type myocardial markers is specifically absent from the Tbx3 expression domain. Tbx3 is able to repress Nppa and Cx40 promoter activity and abolish the synergistic activation of the Nppa promoter by Tbx5 and Nkx2.5. Conclusion: We identified the T-box transcription factor Tbx3 as a novel and accurate marker for the central conduction system. Our analysis implicates a role for Tbx3 in repressing a chamber-specific program of gene expression in regions from which the components of the central conduction system are subsequently formed.
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
Authors: Christine A. Bricault, Karina Yusim, Michael S. Seaman, Hyejin Yoon, James Theiler, Elena E. Giorgi, Kshitij Wagh, Maxwell Theiler, Peter Hraber, Jennifer P. Macke, Edward F. Kreider, Gerald H. Learn, Beatrice H. Hahn, Johannes F. Scheid, James M. Kovacs, Jennifer L. Shields, Christy L. Lavine, Fadi Ghantous, Michael Rist, Madeleine G. Bayne, George H. Neubauer, Katherine McMahan, Hanqin Peng, Coraline Chéneau, Jennifer J. Jones, Jie Zeng, Christina Ochsenbauer, Joseph P. Nkolola, Kathryn E. Stephenson, Bing Chen, S. Gnanakaran, Mattia Bonsignori, LaTonya D. Williams, Barton F. Haynes, Nicole Doria-Rose, John R. Mascola, David C. Montefiori, Dan H. Barouch, Bette Korber
Journal: Cell Host & Microbe (2019)

(Cell Host & Microbe 25, 59–72.e1–e8, January 9, 2019) In Table S3 of the originally published version of this article, details regarding the statistical support for certain signatures were inadvertently omitted by the authors. An updated version of Table S3 is now provided online. The associated legend remains unchanged, and the updating of Table S3 does not impact any conclusions of the study. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine DesignBricault et al.Cell Host & MicrobeJanuary 09, 2019In BriefHIV-1 Env amino acid signatures associated with sensitivity to broadly neutralizing antibodies were systematically defined from large neutralization panels. V2 signatures were incorporated in a trivalent vaccine to enhance epitope exposure and to include common epitope variants, resulting in increased neutralization breadth against heterologous viruses in a guinea pig model. Full-Text PDF Open Access
Studies From the Yale Psychologic Laboratory.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDU-12. CD271 (P75NTR) AS A NOVEL DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR SHH MEDULLOBLASTOMA
Authors: Lisa Liang, Ludivine Coudiere-Morrison, Nazanin Tatari, Vijay Ramaswamy, Timothy Ryken, Marc Del Bigio, Cynthia Hawkins, Jennifer Chan, Tamra Werbowetski-Ogilvie
Journal: Neuro-Oncology (2017)

Medulloblastoma (MB) is the most common malignant primary brain tumor and is currently classified into 5 distinct molecular subtypes based on genomic alterations, gene expression profile, response to treatment and cell of origin. This extensive heterogeneity has revealed a critical need for subtype-specific, functionally validated biomarkers and therapeutic strategies. Using an unbiased high throughput flow cytometry screen and gain/loss of function studies, we previously identified CD271/p75NTR as a candidate stem/progenitor cell marker, specifically in SHH MB. Here, we show that CD271+ and CD271- subpopulations do not exhibit a hierarchal organization; but are rather two co-existing cellular subsets. FACS sorting followed by re-culturing of CD271- and CD271+ cells from low passage primary cultures demonstrated that both cell populations can recapitulate the parental phenotype. However, global gene expression profiling by RNA sequencing revealed that genes/pathways associated with cell survival, proliferation and motility are downregulated in CD271- vs. CD271+ subpopulations. Cell cycle analysis supported these findings and demonstrated that CD271- cells exhibited a decrease in proliferation compared to CD271+ cells. Moreover, PI3K/AKT, JAK/STAT, and NFkB, are downregulated in CD271- vs. CD271+ cells, while pathways such as RAS/MYC are upregulated in CD271- vs. CD271+ cells. Immunohistochemical (IHC) analysis of CD271 levels across the MB subtypes demonstrated that nearly all SHH tumors express CD271, while Group 3 tumors exhibit moderate staining. In contrast, Group 4 MB and WNT do not express CD271. Importantly SHH MB exhibit a nodular CD271 staining pattern, further underscoring the heterogeneity within these tumors and supporting our findings that CD271- and CD271+ cells are distinct, yet clinically relevant, subpopulations. Our results suggest that CD271, in combination with other markers, could be effectively utilized as a diagnostic tool for SHH MB and that therapeutic strategies concomitantly targeting both CD271+ and CD271- subpopulations would be the most effective in SHH MB treatment.
A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.
Authors: Jesús F. San-Miguel, Orhan Sezer, David Siegel, Andreas Guenther, Maria-Victoria Mateos, Ian Prosser, Michele Cavo, Joan Blade, Mario Boccadoro, Bourras R. Bengoudifa, Martin Klebsattel, Priscille M. Bourquelot, Kenneth C. Anderson
Journal: Blood (2009)
From the Centers for Disease Control. Foodborne nosocomial outbreak of Salmonella
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Author Affiliation
Journal: JAMA Internal Medicine (2019)

Liana C. Del Gobbo, PhD; Fumiaki Imamura, PhD; Stella Aslibekyan, PhD; Matti Marklund, PhD; Jyrki K. Virtanen, PhD; Maria Wennberg, PhD; Mohammad Y. Yakoob, PhD; Stephanie E. Chiuve, ScD; Luicito dela Cruz, PhD; Alexis C. Frazier-Wood, PhD; Amanda M. Fretts, MPH, PhD; Eliseo Guallar, PhD; Chisa Matsumoto, PhD, MD; Kiesha Prem, MSc; Tosh Tanaka, PhD; Jason H. Y. Wu, PhD; Xia Zhou, PhD; Catherine Helmer, MD, PhD; Erik Ingelsson, MD, PhD; Jian-Min Yuan, MD, PhD; Pascale Barberger-Gateau, PhD; Hannia Campos, PhD; Paulo H. M. Chaves, MD, PhD; Luc Djoussé, MD, ScD; Graham G. Giles, PhD; Jose Gómez-Aracena, PhD; Allison M. Hodge, PhD; Frank B. Hu, PhD, MD, MPH; Jan-Håkan Jansson, MD, PhD; Ingegerd Johansson, PhD; Kay-Tee Khaw, PhD, MD; Woon-Puay Koh, PhD; Rozenn N. Lemaitre, PhD, MPH; Lars Lind, PhD; Robert N. Luben, PhD; Eric B. Rimm, ScD; Ulf Risérus, PhD, MD; Cecilia Samieri, PhD; Paul W. Franks, PhD; David S. Siscovick, MPH, MD; Meir Stampfer, DrPH, MD; Lyn M. Steffen, PhD, MPH; Brian T. Steffen, PhD; Michael Y. Tsai, PhD; Rob M. van Dam, PhD; Sari Voutilainen, PhD; Walter C. Willett, DrPH, MD; Mark Woodward, PhD; Dariush Mozaffarian, MD, DrPH; for the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCe)
Public Warning About Herbal Product "Chaparral"
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE BACTERIOLOGY OF PERITONITIS
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The hematologic consequences of transjugular intrahepatic portosystemic shunt
Authors: A SANYAL
Journal: Hepatology (1996)

Transjugular intrahepatic portosystemic shunts (TIPS) are a recent innovation in the management of portal hypertension. In 1992, we had previously described an instance of severe hemolysis associated with this procedure. This study was undertaken to define and quantify the true incidence of TIPS-associated hemolysis and its clinical spectrum, as well as to test the hypothesis that portal decompression by TIPS would ameliorate hypersplenism in patients with portal hypertension. A total of 60 patients undergoing TIPS for prevention of recurrent variceal hemorrhage (n = 40) or refractory ascites (n = 20) were studied. Forty patients with cirrhosis who were followed concurrently served as controls. At entry, both groups were comparable with the exception of increased ascites in the TIPS group. A total of 7 instances of intravascular hemolysis were identified in 60 TIPS patients, whereas none occurred in controls. Of these, 4 patients were asymptomatic and detected on routine laboratory testing. Hemolysis led to a greater than 4-g/dL decrease in hemoglobin in 2 patients, 2- to 3-g/dL decrease in 2 others and a 3- to 4-gm/dL decrease in 1 patient. Two patients were able to compensate for hemolysis and did not develop anemia. In all but 1 case, the findings of hemolysis subsided by 12 to 15 weeks; in 1 patient, orthotopic liver transplantation was associated with resolution of the hemolysis. Overall, no significant changes in white blood cell or platelet counts were observed in patients undergoing TIPS despite adequate portal decompression. We conclude that TIPS-induced hemolysis occurs in approximately 10% of subjects. However, it is self-limited and rarely requires intervention. Potential mechanisms of such hemolysis are discussed. TIPS is also not recommended as a means of improving platelet counts in patients with severe hypersplenism.
Correction
Journal: Thorax (2013)

We wish to report a single error in our paper on associations of population and primary healthcare factors with hospital admission rates for chronic obstructive pulmonary disease.An observant researcher has questioned an R squared value for a univariate analysis at primary care trust level.In our paper we reported that about 14.4% of the variance in hospital admissions was explained by GP supply.We have re-run the analyses and confirm that there was a typographical error on our part.The R squared value of 14.4% was actually for the variable GP list size and not for GP supply (the latter has a R squared of 0.1%).The rest of the values are correct.We consider that this correction has no effect on the overall conclusions of our paper, as the important findings were at general practice level.
The sugiura-futagawa procedure (SFP) for bleeding portal hypertension low risk patients. A 14 years experience in Mexico H. Orozco, M.A. Mercado, G. Rojas, E. Prado, C. Chan, G. Salas, J. Hernández. Instituto Nacional de la Nutrición Salvador Zubirán. México, D. F.
Journal: Hepatology (1994)
Chemotherapy of Cancer
Authors: Thomas C. Hall, Genevieve Cole
Journal: New England Journal of Medicine (1962)

Alkylating Compounds Definition and mode of action. An alkylating agent is capable of combining with chemical groups of cell components. The biologically active alkylating agents can combine with metabolically important groups and render them relatively incapable of functioning in their usual fashion in the economy of the cell. An excellent discussion of the alkylating agents appears in the Transactions of the Cancer Conference on Comparative Clinical and Biological Effects of Alkylating Agents held by the New York Academy of Sciences in March, 1957.52 The mode of action of nitrogen mustardlike compounds is outlined in Figure 4. The first step is the . . .
Low cholesterol level as risk factor for noncoronary death in middle-aged men
Authors: B. Peterson
Journal: JAMA (1981)

Eighty-six deaths occurred zero to five years (mean, 2.5 years) after the screening investigation in 10,000 middle-aged men in Malmö, Sweden. The men were 47 to 50 years old at the time of the screening and represented 75% of their total birth-year cohorts in Malmö. The mortality showed two peaks, one at the higher end of the cholesterol distribution and the other and more pronounced one at the lower end of the cholesterol distribution. The first peak corresponded to the cardiovascular deaths while the second peak corresponded to the noncoronary death causes, including alcohol-related deaths. (<i>JAMA</i>1981;245:2056-2057)
Correction
Journal: BMJ (1952)

General Council of the Bar ?" The witness replied that he ,had asked the Law Society, upon which his Lordship shook his head, " Ah, that's quite another thing."One saw in Chancery Court III an exhibition at its best of the British way of settling a dispute.But as the chairman of the General Medical Services Committee remarked when he came into court on the first day, " What a pity that these two parties, both interested in the health of the people, are on opposite sides!"